# An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)

> **NCT05879614** · PHASE2 · WITHDRAWN · sponsor: **Neuren Pharmaceuticals Limited**

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** NNZ-2591

## Key facts

- **NCT ID:** NCT05879614
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Revised development strategy
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879614, "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05879614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*